WELLMED

ANNOUNCEMENT / PRESS RELEASE

U.S. based Pharmaceutical Company Conrex Pharmaceuticals recently finalized an agreement with Dublin based company, Wellmed Ireland, to market and distribute its international award winning skin care product range in Ireland. This agreement will create 120 career and business opportunities across Ireland/Conrex Pharmaceuticals is the patent holder of the FDA – approved Permeation Enhancement Technology (PET™). This technology is now commonly used to transfer medication through the skin as an alternative to tablets and injections as seen in anti-smoking patches, hormone and morphine patches.

Conrex Pharmaceuticals has now developed a skin therapy product range known as SESHA. All of the SESHA products use the same PET™ technology to set a new standard and benchmark for product penetration and efficacy in the cosmetic skin care market worldwide. This unique technology resulted in the SESHA range winning the coveted Aesthetic Product of the Year – Aesthetic Medicine Award in 2009.

Wellmed Ireland is privileged to launch the SESHA range, which was scientifically researched and developed by Harvard and MIT educated, Dr.Dean Hsieh. This innovative discovery and subsequent development of an affordable, commercial product range has revolutionised the skin care industry worldwide and has proven to be highly successful in its marketing, sales and market share in Europe, the U.S. and Asia.